Clinical Outcomes for Previously Treated Patients with Advanced Gastric or Gastroesophageal Junction Cancer : A Systematic Literature Review and Meta-Analysis
© 2023. The Author(s)..
PURPOSE: Although second-line treatments improve survival compared to best supportive care in patients with advanced gastric cancer with disease progression on first-line therapy, prognosis remains poor. A systematic review and meta-analysis were conducted to quantify the efficacy of second-or-later line systemic therapies in this target population.
METHODS: A systematic literature review (January 1, 2000 to July 6, 2021) of Embase, MEDLINE, and CENTRAL with additional searches of 2019-2021 annual ASCO and ESMO conferences was conducted to identify studies in the target population. A random-effects meta-analysis was performed among studies involving chemotherapies and targeted therapies relevant in treatment guidelines and HTA activities. Outcomes of interest were objective response rate (ORR), overall survival (OS), and progression-free survival (PFS) presented as Kaplan-Meier data. Randomized controlled trials reporting any of the outcomes of interest were included. For OS and PFS, individual patient-level data were reconstructed from published Kaplan-Meier curves.
RESULTS: Forty-four trials were eligible for the analysis. Pooled ORR (42 trials; 77 treatment arms; 7256 participants) was 15.0% (95% confidence interval (CI) 12.7-17.5%). Median OS from the pooled analysis (34 trials; 64 treatment arms; 60,350 person-months) was 7.9 months (95% CI 7.4-8.5). Median PFS from the pooled analysis (32 trials; 61 treatment arms; 28,860 person-months) was 3.5 months (95% CI 3.2-3.7).
CONCLUSION: Our study confirms poor prognosis among patients with advanced gastric cancer, following disease progression on first-line therapy. Despite the approved, recommended, and experimental systemic treatments available, there is still an unmet need for novel interventions for this indication.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Journal of gastrointestinal cancer - 54(2023), 4 vom: 01. Dez., Seite 1031-1045 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abderhalden, Lauren A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chemotherapy |
|---|
| Anmerkungen: |
Date Completed 29.12.2023 Date Revised 31.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12029-023-00932-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357221192 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357221192 | ||
| 003 | DE-627 | ||
| 005 | 20240108140712.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12029-023-00932-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1246.xml |
| 035 | |a (DE-627)NLM357221192 | ||
| 035 | |a (NLM)37219679 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Abderhalden, Lauren A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical Outcomes for Previously Treated Patients with Advanced Gastric or Gastroesophageal Junction Cancer |b A Systematic Literature Review and Meta-Analysis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.12.2023 | ||
| 500 | |a Date Revised 31.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a PURPOSE: Although second-line treatments improve survival compared to best supportive care in patients with advanced gastric cancer with disease progression on first-line therapy, prognosis remains poor. A systematic review and meta-analysis were conducted to quantify the efficacy of second-or-later line systemic therapies in this target population | ||
| 520 | |a METHODS: A systematic literature review (January 1, 2000 to July 6, 2021) of Embase, MEDLINE, and CENTRAL with additional searches of 2019-2021 annual ASCO and ESMO conferences was conducted to identify studies in the target population. A random-effects meta-analysis was performed among studies involving chemotherapies and targeted therapies relevant in treatment guidelines and HTA activities. Outcomes of interest were objective response rate (ORR), overall survival (OS), and progression-free survival (PFS) presented as Kaplan-Meier data. Randomized controlled trials reporting any of the outcomes of interest were included. For OS and PFS, individual patient-level data were reconstructed from published Kaplan-Meier curves | ||
| 520 | |a RESULTS: Forty-four trials were eligible for the analysis. Pooled ORR (42 trials; 77 treatment arms; 7256 participants) was 15.0% (95% confidence interval (CI) 12.7-17.5%). Median OS from the pooled analysis (34 trials; 64 treatment arms; 60,350 person-months) was 7.9 months (95% CI 7.4-8.5). Median PFS from the pooled analysis (32 trials; 61 treatment arms; 28,860 person-months) was 3.5 months (95% CI 3.2-3.7) | ||
| 520 | |a CONCLUSION: Our study confirms poor prognosis among patients with advanced gastric cancer, following disease progression on first-line therapy. Despite the approved, recommended, and experimental systemic treatments available, there is still an unmet need for novel interventions for this indication | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Chemotherapy | |
| 650 | 4 | |a Meta-analysis | |
| 650 | 4 | |a Metastatic gastric cancer | |
| 650 | 4 | |a Pretreated gastric cancer | |
| 650 | 4 | |a Systematic literature review | |
| 650 | 4 | |a Targeted therapy | |
| 700 | 1 | |a Wu, Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Amonkar, Mayur M |e verfasserin |4 aut | |
| 700 | 1 | |a Lang, Brian M |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Sukrut |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Fan |e verfasserin |4 aut | |
| 700 | 1 | |a Frederickson, Andrew M |e verfasserin |4 aut | |
| 700 | 1 | |a Mojebi, Ali |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of gastrointestinal cancer |d 2007 |g 54(2023), 4 vom: 01. Dez., Seite 1031-1045 |w (DE-627)NLM182605981 |x 1941-6636 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2023 |g number:4 |g day:01 |g month:12 |g pages:1031-1045 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12029-023-00932-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2023 |e 4 |b 01 |c 12 |h 1031-1045 | ||